Product Description
Mechanisms of Action: TNFS10A Agonist,TNFS10B Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Lymphoma, Non-Hodgkin
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016L04304 | P3 |
Unknown status |
Non-Small-Cell Lung Cancer |
2017-10-01 |
|
| APO4565g | P1 |
Completed |
Colorectal Cancer |
2014-03-01 |
|
| APO3583g | P1 |
Completed |
Colorectal Cancer |
2012-03-01 |
|
| APO3585g | P2 |
Terminated |
Lymphoma, Non-Hodgkin |
2010-05-01 |